

The Applicants were notified on April 11, 2002 by an unidentified individual at the USPTO that the original copy of the computer-readable form of the Sequence Listing filed January 13, 2002 was damaged due to treatment given to all incoming mail.

In the preparation of the requested replacement disk it was determined that the originally filed sequence listing contained a number of inaccuracies. Thus, instead of submitting a replacement computer readable version of the Sequence Listing filed January 13, 2002, Applicants now submit both paper and computer readable versions of a Substitute Sequence Listing to replace the Sequence Listing filed January 13, 2002.

This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOS:1-252, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the Specification and Abstract by the current Amendment. The attached pages are captioned

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

  
Andrew T. Serafini  
Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
ATS:adm  
PA 3215519 v1

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph beginning at line 22 of page 14 has been amended as follows:

Figure 15C lists ZFP target sequences (SEQ ID NOS:207, 144 and 240, respectively) and finger designs (SEQ ID NOS:239, 238, 122, 57, 159, 35, 64, 85, 36, 112, 66 and 54, respectively). ZFPs are named according to target site location and the suffix mVZ (for mouse VEGF-A ZFP). Finger designs indicate the identity of amino acid residues at positions -1 to +6 of the alpha helix of each finger.

Paragraph beginning at line 26 of page 14 has been amended as follows:

Figure 15D shows gel-shift assays of binding affinity. A three-fold dilution series of each protein was tested for binding to its DNA target (SEQ ID NOS:207, 144, 240 and 141, respectively), with the highest concentration in lane 10 and the lowest concentration in lane 2. Lane 1 contains probe alone. Apparent  $K_d$ 's, derived from the average of 3 such studies, are indicated at right. For mVZ+426 and mVZ+509,  $K_d$ 's are provided as upper bounds ( $<0.01$  nM), since the use of 0.01 nM of probe has probably led to an underestimate of the affinity of these proteins.

Paragraph beginning at line 20 of page 17 has been amended as follows:

The term "zinc finger protein" or "ZFP" refers to a protein having DNA binding domains that are stabilized by zinc. The individual DNA binding domains are typically referred to as "fingers" A ZFP has least one finger, typically two, three, four, five, six or more fingers. Each finger binds from two to four base pairs of DNA, typically three or

four base pairs of DNA. A ZFP binds to a nucleic acid sequence called a target site or target segment. Each finger typically comprises an approximately 30 amino acid, zinc-chelating, DNA-binding subdomain. An exemplary motif characterizing one class of these proteins (C<sub>2</sub>H<sub>2</sub> class) is -Cys-(X)<sub>2-4</sub>-Cys-(X)<sub>12</sub>-His-(X)<sub>3-5</sub>-His (SEQ ID NO:208) (where X is any amino acid). Additional classes of zinc finger proteins are known and are useful in the practice of the methods, and in the manufacture and use of the compositions disclosed herein (see, e.g., Rhodes et al. (1993) *Scientific American* 268:56-65). Studies have demonstrated that a single zinc finger of this class consists of an alpha helix containing the two invariant histidine residues coordinated with zinc along with the two cysteine residues of a single beta turn (see, e.g., Berg & Shi, *Science* 271:1081-1085 (1996)).

Paragraph beginning at line 3 of page 34 has been amended as follows:

The zinc finger proteins (ZFPs) disclosed herein are proteins that can bind to DNA in a sequence-specific manner. As indicated supra, these ZFPs can be used in a variety of applications, including modulating angiogenesis and in treatments for ischemia. An exemplary motif characterizing one class of these proteins, the C<sub>2</sub>H<sub>2</sub> class, is -Cys-(X)<sub>2-4</sub>-Cys-(X)<sub>12</sub>-His-(X)<sub>3-5</sub>-His (SEQ ID NO:208) (where X is any amino acid) [(SEQ. ID. NO:\_\_\_)]. Several structural studies have demonstrated that the finger domain contains an alpha helix containing the two invariant histidine residues and two invariant cysteine residues in a beta turn coordinated through zinc. However, the ZFPs provided herein are not limited to this particular class. Additional classes of zinc finger proteins are known and can also be used in the methods and compositions disclosed herein (see, e.g., Rhodes, et al. (1993) *Scientific American* 268:56-65). In certain ZFPs, a single finger domain is about 30 amino acids in length. Zinc finger domains are involved not only in DNA-recognition, but also in RNA binding and in protein-protein binding.

Paragraph beginning at line 3 of page 36 has been amended as follows:

Tables 3 and 4 show the amino acid sequences of a number of different ZFPs and the corresponding target sites to which they bind. Table 3 lists ZFPs that bind to target sites that include 9 nucleotides. The first column in this table lists an internal reference name of the ZFP. Column 2 includes the 9 base target site bound by a three-finger zinc finger protein, with the target sites listed in 5' to 3' orientation. The corresponding SEQ ID NO: [SEQ ID NO.] for the target site is listed in column 3 (SEQ ID NOS:1-29 and 244). The amino acid sequences of portions of the three zinc finger components involved in recognition are listed in columns 4, 6 and 8, and their corresponding SEQ ID NOS: [SEQ ID NOS]. are listed in columns 5 (SEQ ID NOS:30-58), 7 (SEQ ID NOS:59-87, 112, and 245-252) and 9 (SEQ ID NOS:42, 64, and 88-116), respectively. The numbering convention for zinc fingers is defined below. Column 10 lists the dissociation constants for some of the ZFP/target site complexes. Methods for determining such constants are described *infra*. Excluding cross-strand interactions, each finger binds to a triplet of bases (a target subsite) within a corresponding target sequence. The first finger binds to the first triplet starting from the 3' end of a target site, the second finger binds to the second triplet, and the third finger binds the third (i.e., the 5'-most) triplet of the target sequence. Thus, for example, the RSDHLAR finger (SEQ ID NO:30) [(SEQ ID NO:\_\_\_)] of the ZFP BVO 13A (first column of Table 3) binds to 5'GGG3', the DRSNLTR finger (SEQ ID NO:59) [(SEQ ID NO:\_\_\_)] binds to 5'GAC3' and the RSDALTQ finger (SEQ ID NO:88) [(SEQ ID NO:\_\_\_)] binds to 5'ATG3'.

Paragraph beginning at line 20 of page 36 has been amended as follows:

Table 4 provides information on six-finger ZFPs targeting VEGF genes. Table 4 has a similar format to Table 3, with column 1 indicating the internal reference name of the ZFP. In contrast to Table 3, however, column 2 of Table 4 includes the 18 base target site recognized by a six-finger protein (here, too, targets are listed in a 5' to 3' orientation), with the corresponding SEQ ID NO: [SEQ ID NO.] listed in column 3 (SEQ ID NOS:117-119). The amino acid sequences of portions of the six zinc finger components involved in

recognition are listed in columns 4, 6, 8, 10, 12 and 14, with associated SEQ ID NOS: [SEQ ID NOS.] being listed in columns 5 (SEQ ID NOS:120-122), 7 (SEQ ID NOS:123-125), 9 (SEQ ID NOS:126-128), 11 (SEQ ID NOS:129-131), 13 (SEQ ID NOS:132-134) and 15 (SEQ ID NOS:135-17), respectively. In ZFPs of this type, the first finger binds to the first triplet starting from the 3' end of a target site, the second finger binds to the second triplet, the third finger binds the third triplet, the fourth finger binds to the fourth triplet, the fifth finger binds to the fifth triplet and the sixth finger binds to the sixth (i.e., the 5'-most) triplet of the target sequence (again excluding cross-strand interactions). Hence, for the ZFP named BVO 10A-9A, the first finger QSSDLRR (SEQ ID NO:120) [(SEQ ID NO: \_\_)] binds 5'GCT3', the second finger RSDHLTR (SEQ ID NO:123) [(SEQ ID NO: \_\_)] binds 5'GGG3', the third finger DRSALAR (SEQ ID NO:126) [(SEQ ID NO: \_\_)] binds 5'GTC3', the fourth finger RSDHLAR (SEQ ID NO:129) [(SEQ ID NO: -)] binds 5'GGG3', the fifth finger RSDNLAR (SEQ ID NO:132) [(SEQ ID NO: \_\_)] binds 5'GAG3' and the sixth finger RSDALTR (SEQ ID NO:135) [(SEQ ID NO: \_\_)] binds 5'GTG3'.

Paragraph beginning at line 26 of page 38 has been amended as follows:

The relative order of fingers in a zinc finger protein from N-terminal to C-terminal determines the relative order of triplets in the 3' to 5' direction in the target. For example, if a zinc finger protein comprises from N-terminal to C-terminal first, second and third fingers that individually bind, respectively, to triplets 5' GAC3', 5'GTA3' and 5'GGC3' then the zinc finger protein binds to the target segment 3'CAGATGCGG5' (SEQ ID NO:209) [(SEQ ID NO: \_\_)]. If the zinc finger protein comprises the fingers in another order, for example, second finger, first finger, third finger, then the zinc finger protein binds to a target segment comprising a different permutation of triplets, in this example, 3'ATGCAGCGG5' (SEQ ID NO:210) [(SEQ ID NO: \_\_)]. See Berg & Shi, *Science* 271, 1081-1086 (1996). The assessment of binding properties of a zinc finger protein as the aggregate of its component fingers may, in some cases, be influenced by context-dependent interactions of multiple fingers binding in the same protein.

Paragraph beginning at line 16 of page 39 has been amended as follows:

Linkage can be accomplished using any of the following peptide linkers. T G E K P (SEQ ID NO:211); [(SEQ ID NO:\_\_\_)] (Liu et al., 1997, supra.); (G<sub>4</sub>S)<sub>n</sub> (SEQ ID NO:212); [(SEQ ID NO:\_\_\_)] (Kim et al., Proc. Natl. Acad. Sci. U.S.A. 93: 1156-1160 (1996.); GGRRGGGS (SEQ ID NO:213); [(SEQ ID NO:\_\_\_)] LRQRDGERP (SEQ ID NO:214); [(SEQ ID NO:\_\_\_)] LRQKDGGGSERP (SEQ ID NO:215); [(SEQ ID NO:\_\_\_)] LRQKD(G<sub>3</sub>S)<sub>2</sub>ERP (SEQ ID NO:216). [(SEQ ID NO:\_\_\_)] Alternatively, flexible linkers can be rationally designed using computer programs capable of modeling both DNA-binding sites and the peptides themselves or by phage display methods. In a further variation, noncovalent linkage can be achieved by fusing two zinc finger proteins with domains promoting heterodimer formation of the two zinc finger proteins. For example, one zinc finger protein can be fused with fos and the other with jun (see Barbas et al., WO 95/119431).

Paragraph beginning at line 31 of page 39 has been amended as follows:

A component finger of zinc finger protein typically contains about 30 amino acids and, in one embodiment, has the following motif (N-C) (SEQ ID NO:208):

[(SEQ ID NO:\_\_\_)]

Cys-(X)<sub>2-4</sub>-Cys-X.X.X.X.X.X.X.X.X.X.X.X-His-(X)<sub>3-5</sub>-His

-1 1 2 3 4 5 6 7

Paragraph beginning at line 14 of page 40 has been amended as follows:

The ZFPs provided herein are engineered to recognize a selected target site in a VEGF gene such as shown in Tables 3, 4 and 6. The process of designing or selecting a ZFP typically starts with a natural ZFP as a source of framework residues. The process of design or selection serves to define nonconserved positions (i.e., positions -1 to +6) so as to confer a

desired binding specificity. One suitable ZFP is the DNA binding domain of the mouse transcription factor Zif268. The DNA binding domain of this protein has the amino acid sequence:

YACPVECDRRFSRSDDELTRHIRIHTGQKP (F1) (SEQ ID NO:217) [(SEQ ID NO: \_\_\_\_)]  
FQCRICMRNFSRSDHLTTHIRHTGQKP (F2) (SEQ ID NO:218) [(SEQ ID NO: \_\_\_\_)]  
FACDICGRKFARSDERKRHTKIHLRQK (F3) (SEQ ID NO:219) [(SEQ ID NO: \_\_\_\_)]  
and binds to a target 5' GCG TGG GCG 3' (SEQ ID NO:220) [(SEQ ID NO: \_\_\_\_)].

Paragraph beginning at line 25 of page 40 has been amended as follows:

Another suitable natural zinc finger protein as a source of framework residues is Sp-1. The Sp-1 sequence used for construction of zinc finger proteins corresponds to amino acids 531 to 624 in the Sp-1 transcription factor. This sequence is 94 amino acids in length. The amino acid sequence of Sp-1 is as follows:

PGKKKQHICHIQGCGKVYGKTSHLRAHLRWHTGERPFMCTWSYCGKRFTSRDELQR  
HKRHTGEEKKFACPECPKRFMRSDHLSKHIKTHQNKKG (SEQ ID NO:221) [(SEQ ID  
NO: \_\_\_\_)]

Sp-1 binds to a target site 5'GGG GCG GGG3' (SEQ ID NO:222) [(SEQ ID No: 14)].

Paragraph beginning at line 32 of page 40 has been amended as follows:

An alternate form of Sp-1, an Sp-1 consensus sequence, has the following amino acid sequence:

meklmgsgdPGKKKQHACPECGKSFSKSSHLRAHQRTHTGERPYKCPECGKSFSRSDDEL  
QRHQRTHTGEEKPYKCPECGKSFSRSDHLSKHQRTHTQNKKG (SEQ ID NO:223) [(SEQ  
ID NO: \_\_\_\_)] (lower case letters are a leader sequence from Shi & Berg, *Chemistry and  
Biology* 1, 83-89. (1995). The optimal binding sequence for the Sp-1 consensus sequence is  
5'GGGGCGGGG3' (SEQ ID NO:222) [(SEQ ID NO: \_\_\_\_)]. Other suitable ZFPs are  
described below.

Paragraph beginning at line 22 of page 74 has been amended as follows:

*Construction of Zinc Finger Fusion Proteins.* VEGF-A-targeted zinc fingers were assembled in an SP1 backbone and cloned into the pcDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA) as described previously (Zhang et al., supra; WO 00/41566; and WO 00/42219). A CMV promoter was used to drive the expression of all the ZFPs in mammalian cells. All ZFP constructs contained an N-terminal nuclear localization signal (Pro-Lys-Lys-Lys-Arg-Lys-Val; SEQ ID NO:224, [SEQ ID NO: \_\_\_\_]) from SV40 large T antigen, a Zinc Finger DNA-binding domain, an activation domain, and a FLAG peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys; SEQ ID NO:225, [SEQ ID NO: \_\_\_\_]). ZFP-VP16 fusions contained the herpes simplex virus VP16 activation domain from amino acid 413 to 490 (Sadowski et al., supra; Zhang et al, supra; WO 00/41566; and WO 00/42219). ZFP-p65 fusions contained the human NF- $\kappa$ B transcription factor p65 subunit (amino acid 288-548) as the activation domain (Ruben et al., supra).

Paragraph (TABLE 5) beginning at line 22 of page 74 has been amended as follows:



TABLE 5: NUCLEOTIDE SEQUENCES OF PRIMERS AND PROBES USED FOR  
TAQMAN ANALYSIS

	Sequence	SEQ ID NO:
VEGF-A forward primer	5'-GTGCATTGGAGCCTTGCCTTG-3'	<u>226</u>
VEGF-A reverse primer	5'-ACTCGATCTCATCAGGGTACTC-3'	<u>227</u>
VEGF-A Taqman Probe	5'-FAM-CAGTAGCTGCGCTGATAGACATCCA-TAMRA-3'	<u>228</u>
GAPDH forward primer	5'-CCATGTTTCGTCATGGGTGTGA-3'	<u>229</u>
GAPDH reverse primer	5'-CATGGACTGTGGTCATGAGT-3'	<u>230</u>
GAPDH Taqman Probe	5'-FAM-TCCTGCACCACCAACTGCTTAGCA-TAMRA-3'	<u>231</u>
VP16-FLAG forward primer	5'-CATGACGATTTTCGATCTGGA-3'	<u>232</u>
VP16-FLAG reverse primer	5'-CTACTTGTTCATCGTCGTCCTTG-3'	<u>233</u>
VP16-FLAG Taqman Probe	5'-FAM-ATCGGTAAACATCTGCTCAAACCTCGA-TAMRA-3'	<u>234</u>

Abbreviations: FAM: aminofluorescein; TAMRA: tetramethylrhodamine

Paragraph beginning at line 1 of page 78 has been amended as follows:

Analysis of splice variants of VEGF-A mRNA - To detect the multiple splice variants of VEGF-A mRNA, total RNA samples (0.5 µg) were subjected to a 20-cycle RT-PCR reaction using Titan™ one-tube RT-PCR system (Roche Molecular Biochemicals, Indianapolis, IN). The primers used were 5'-ATGAACTTTCTGCTGTCTTGGGTGCATT-3' (SEQ ID NO:235) [(SEQ ID NO: \_\_\_\_\_)], and 5'-TCACCGCCTCGGCTTGTCACAT-3' (SEQ ID NO:236) [(SEQ ID NO: \_\_\_\_\_)]. The PCR products were resolved on a 3% Nusieve 3:1 agarose gel (FMC, Rockland, ME), blotted onto a Nytran SuperCharge membrane (Schleicher & Schuell, Keene, NH), and analyzed by Southern hybridization using a <sup>32</sup>P-labeled human VEGF-A165 antisense riboprobe. The expected PCR product sizes for VEGF-189, VEGF-165 and VEGF-120 were 630, 576, and 444 bp, respectively.

Paragraph beginning at line 29 of page 85 has been amended as follows:

The sequence of the murine VEGF gene (GenBank Accession Number U41383) was searched for ZFP target sites and a ZFP, denoted VG10A/8A, was designed to bind to a site between 56 and 73 nucleotides downstream of the transcriptional startsite. The sequence of this target site is 5'-TGAGCGGCGGCAGCGGAG (SEQ ID NO:237) [(SEQ ID NO: \_\_)]. The six-finger ZFP designed to bind this target site has the following amino acid sequences in the recognition helices (proceeding in an N-terminal to C-terminal direction): RSDNLAR (SEQ ID NO:35) [(SEQ ID NO: \_\_)]; RSDQLQR (SEQ ID NO:159) (SEQ ID NO: \_\_); QSGSLTR (SEQ ID NO:57) [(SEQ ID NO: \_\_)]; RSDQLTR (SEQ ID NO:122) [(SEQ ID NO: \_\_)]; RSDQLSR (SEQ ID NO:238); [(SEQ ID NO: \_\_)] and QSGHLTK (SEQ ID NO:239) [(SEQ ID NO: \_\_)]. This six-finger binding domain was fused to a VP16 activation domain, according to methods described in Example 1. A plasmid encoding this ZFP fusion was co-transfected into mouse cells with a reporter gene under the control of the murine VEGF promoter, and a 29-fold activation of reporter gene activity was observed.

Paragraph beginning at line 22 of page 89 has been amended as follows:

To assemble the gene encoding the six-finger protein mVZ+57, the following two-step strategy was utilized. First, genes encoding three finger proteins corresponding to fingers 1-3 and 4-6 of VZ+57 were constructed and cloned as above, yielding constructs pMal-c2 '1-3' and pMal-c2 '4-6'. Next, these two genes were joined via a short DNA spacer encoding a flexible peptide linker. This was accomplished as follows: (i) PCR of the '4-6' ZFP gene using the primers 5' CCCAGATCTGGTGATGGCAAGAAGAAGCAGCACCATCTGCCACATCCAG (SEQ ID NO:241) [(SEQ ID NO: \_\_)] and 5' CCCAAGCTTAGGATCCACCCTTCTTGTTCTGGTGGGT (SEQ ID NO:242) [(SEQ ID NO: \_\_)]; (ii) digestion of the resultant fragment with Bgl II and Hind III (sites underlined in primers); and (iii) ligation into the BamHI and Hind III sites of the pMal-c2 '1-3'. The resultant protein, VZ+57, consists of the '1-3' and '4-6' three-finger modules connected by a flexible peptide linker, with the amino acid sequence between the second zinc-coordinating

histidine of finger 3 and the first zinc-coordinating cysteine of finger 4 (both underlined) as follows: HQNKKGGSGDGKKKQHIC (SEQ ID NO:243).

Paragraph beginning at line 15 of page 90 has been amended as follows:

Construction of retroviral vectors. The retroviral vectors described here are derived from a pLXSN, a Moloney murine leukemia virus-based vector containing a neomycin resistance gene under the control of an internal simian virus (SV40) promoter. Using EcoR1 and Xho1 restriction sites, the zinc finger expression cassette was placed immediately downstream of the LTR in pLXSN. Briefly, all ZFP constructs contained an N-terminal nuclear localization signal (Pro-Lys-Lys-Lys-Arg-Lys-Val; SEQ ID NO:224) from SV40 largeT antigen, a Zinc Finger DNA-binding domain, the herpes simplex virus VP16 activation domain from amino acid 413 to 490, and a FLAG peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys; SEQ ID NO:224). The LXSN vectors were produced in the 293 AMPHO-PAK<sup>TM</sup> cell line and had titers ranging from 0.5-1.0 x 10<sup>6</sup> G418-resistant colony-forming units. Virus-containing supernatant was collected 48 hr after transfection, filtered through 0.45-mm-pore-size filter and used fresh for transduction of target cells or aliquoted and stored at -80 °C.

Paragraph (TABLE 3) beginning at line 1 of page 104 has been amended as follows:

# PATENT

**TABLE 3** Target sites and recognition helix sequences of human VEGF-targeted ZFPs

ZFP NAME	TARGET	SEQ. ID NO	F 1	SEQ ID NO	F 2	SEQ ID NO	F 3	SEQ ID NO	K <sub>d</sub> (nM)
BVO 13A	ATGGACGGG	1	RSDHLAR	30	DRSNLTR	59	RSDALTO	88	<.02
EP10A	KGGGGCTGG	2	RSDHLTT	31	DRSHLAR	60	RSDHLSK	89	0.35
GATA82Z678	GAGKGKGYG	3	RLDSLRR	32	DRDHLTR	61	RSDNLAR	90	1.8
HBV 3	GGGGGAGGW	4	QTGHLRR	33	QSGHLQR	62	RSDHLSR	91	30
HP38 4A	GGDTGGGGG	5	RSDHLAR	34	RSDHLTT	63	QRAHLAR	92	0.75
HUM 17A	ARGGGGGAG	6	RSDNLAR	35	RSDHLSR	64	RSDNLTO	93	<.02
HUM 19A	TGGGCAGAC	7	DRSNLTR	36	QSGDLTR	65	RSDHLTT	94	0.02
MTS 5A	TGGGGGTGG	8	RSDHLTT	37	RSDHLTR	66	RSDHLTT	95	0.07
MX1E	ATGGACGGG	9	RSDHLAR	38	DRSNLTR	67	RSDALSA	96	3.4
PDF 5A	GYAGGGGCC	10	DRSSLTR	39	RSDHLSR	68	QSGSLTR	97	.23
RAT 24A	GDGGAAGHC	11	ERGTLAR	40	QSGNLAR	69	RSDALAR	98	<.02
SAN 16A	AKGGAAGGG	12	RSDHLAR	41	QSGNLAR	70	RSDALRQ	99	1.03
USX 3A	GCCGGGGAG	13	RSDNLTR	42	RSDHLTR	71	DRSDLTR	100	0.06
VEGF 1	GGGAGGVK	14	TTSNLRR	43	RSSNLQR	72	RSDHLSR	101	2.83
VEGF 1*	GGGAGGVK	15	TTSNLRR	44	RSSNLQR	73	RSDHLSR	102	3
VEGF 1A	GGGAGGVK	16	TTSNLRR	45	RSDNLQR	74	RSDHLSR	103	0.2
VEGF 1B	GGGAGGAT	17	QSSNLAR	46	RSDNLQR	75	RSDHLSR	104	2
VEGF 1C	GGGAGGAT	18	TTSNLAR	47	RSDNLQR	76	RSDHLSR	105	1
VEGF 1D	GGGAGGMT	19	QSSNLRR	48	RSDNLQR	77	RSDHLSR	106	2
VG 10A	GAWGGGGC	20	DSGHLTR	49	RSDHLTR	78	QSGNLTR	107	ND
VG 1B	ATGGGGGTG	21	RSDALTR	50	RSDHLTR	79	RSDALTO	108	ND
VG 4A	GGGGGCTGG	22	RSDHLTT	51	DRSHLAR	80	RSDHLSR	109	ND
VG 8A	GDGTGGGN	23	QSSHLAR	52	RSDHLTT	81	RSDALAR	110	.35
VOP 28A-2	GGGGGCGCT	24	QSSDLRR	53	DRSHLAR	82	RSDHLSR	111	<.02
VOP 30A-4	GCTGGGGC	25	DRSHLTR	54	RSDHLTR	83	QSSDLTR	112	<.02
ZFP NAME	TARGET	SEQ. ID NO	F 1	SEQ ID NO	F 2	SEQ ID NO	F 3	SEQ ID NO	K <sub>d</sub> (nM)
VOP 32A-6	GGGGGTGAC	26	DRSNLTR	55	MSHLSR	84	RSDHLSR	113	<.02
VOP 32B-7	GGGGGTGAC	27	DRSNLTR	56	TSGHLVR	85	RSDHLSR	114	<.02
VOP 35A-10	GCTGGAGCA	28	QSGSLTR	57	QSGHLQR	86	QSSDLTR	115	<.02
ZEN-7A 1	GGGGHGCT	29	QSSDLRR	58	QSSHLAR	87	RSDHLSR	116	.63
VOP 29A-3	GAGGCTTG	244	RSDHLTT	51	QSSDLTR	112	RSDNLTR	42	<.02

PATENT

VOP 32-C	GGGGGTGAC	26	DRSNLTR	31	TSGHLTR	245	RSDHLSR	68	ND
VOP 32-D	GGGGGTGAC	26	DRSNLTR	36	TSGHLIR	246	RSDHLSR	68	ND
VOP 32-E	GGGGGTGAC	26	DRSNLTR	36	TSGHLSR	247	RSDHLSR	68	ND
VOP 32-F	GGGGGTGAC	26	DRSNLTR	36	TSGHLAR	248	RSDHLSR	68	ND
VOP 32-G	GGGGGTGAC	26	DRSNLTR	36	TSGHLRR	249	RSDHLSR	68	ND
VOP 32-H	GGGGGTGAC	26	DRSNLTR	36	TAGHLVR	250	RSDHLSR	68	ND
VOP 32-I	GGGGGTGAC	26	DRSNLTR	36	TTGHLVR	251	RSDHLSR	68	ND
VOP 32-J	GGGGGTGAC	26	DRSNLTR	36	TKDHLVR	252	RSDHLSR	68	ND

103

Paragraph (TABLE 7) beginning at line 1 of page 107 has been amended as follows:

**TABLE 7** Target sites and recognition helix sequences of  
rat VEGF-targeted ZFPs

ZFP NAME	TARGET	LOCATION	RECOGNITION HELICES
BVO 12A- 11A	GGAGAGGGGGCCGCACTG (SEQ ID NO: 182)	+785	F1: RSDALTR (SEQ ID NO:[ ]186) F2: QSGDLTR (SEQ ID NO:[ ]187) F3: ERGDLTR (SEQ ID NO:[ ]188) F4: RSDHLAR (SEQ ID NO:[ ]189) F5: RSDNLAR (SEQ ID NO:[ ]190) F6: QSSHLAR (SEQ ID NO:[ ]191)
BVO 14A- 13B	ATGGACGGGtGAGGCGGCG (SEQ ID NO: 183)	+830	F1: RSDELTR (SEQ ID NO:[ ]192) F2: RSDELQR (SEQ ID NO:[ ]193) F3: RSDNLAR (SEQ ID NO:[ ]194) F4: RSDHLAR (SEQ ID NO:[ ]195) F5: DRSNLTR (SEQ ID NO:[ ]196) F6: RSDALTQ (SEQ ID NO:[ ]197)
VOP 32A	GGGGGTGAC (SEQ ID NO: 184)	+420	F1: DRSNLTR (SEQ ID NO:[ ]198) F2: MSHHLR (SEQ ID NO:[ ]199) F3: RSDHLR (SEQ ID NO:[ ]200)
VOP 30A	GCTGGGGGC (SEQ ID NO: 185)	+40 +514	F1: DRSHLTR (SEQ ID NO:[ ]201) F2: RSDHLTR (SEQ ID NO:[ ]202) F3: QSSDLTR (SEQ ID NO:[ ]203)
VOP 32B	GGGGGTGAC (SEQ ID NO:26)	+420	F1: DRSNLTR (SEQ ID NO:36) F2: TSGHLVR (SEQ ID NO:168) F3: RSDHLR (SEQ ID NO:64)